Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 6,730 matching trials from the live ClinicalTrials.gov search.
Conditions
Extreme Prematurity, Enteral Nutrition, Bronchopulmonary Dysplasia
Interventions
High-energy group, Standard-energy group
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 3 Days
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Brain Cancer, Choroid Plexus Tumors
Interventions
Carboplatin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Leucovorin, Methotrexate, Temozolomide, Vincristine
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more
Completed Not applicable Interventional Accepts healthy volunteers

Appetite Lexicon Training

NCT04576585
Conditions
Appetitive Behavior
Interventions
Lexicon training
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Lafayette, Indiana
Conditions
Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Melanoma, CRC, Urothelial Carcinoma, Cholangiocarcinoma
Interventions
NC318
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 3 more
Completed Not applicable Interventional Accepts healthy volunteers

Use of Neuromuscular Electrical Stimulation to Prevent Exercise Resistance

NCT07161648
Conditions
Fat Metabolism
Interventions
neuromuscular electrical stimulation
Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Anxiety, Caregiver Burden
Interventions
Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Neoplasms, Melanoma
Interventions
Modakafusp Alfa, Pembrolizumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
15
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 12 more
Completed Not applicable Interventional Results available

Enoxaparin Versus Aspirin in Patients With Cancer and Stroke

NCT01763606
Conditions
Cancer Patients First-ever Acute Ischemic Stroke
Interventions
Enoxaparin, Aspirin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Conditions
Hydroxocobalamin Adverse Reaction
Interventions
Hydroxocobalamin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Prosperando: Fostering Resilience on Dialysis

NCT03978806
Conditions
Racial/Ethnic Minorities on Dialysis
Interventions
Active Comparator: peer navigator, Placebo Comparator: Control Arm (standard of care)
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Kerendia (Finerenone, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
38
States / cities
Huntsville, Alabama • Phoenix, Arizona • Harrisburg, Arkansas + 33 more
Conditions
Recruitment
Interventions
Baseline (control) message, Positively-valenced message, Payment-inclusive message, Positively-valenced, payment-inclusive message
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional

VR AI Meditation for Pain

NCT07122843
Conditions
Pain and Anxiety
Interventions
VR Guided Meditation
Device
Lead sponsor
Christopher Almario
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute
Interventions
Clofarabine, Cytarabine intravenous, Methotrexate, Intrathecal (IT) Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Charlotte, North Carolina • Seattle, Washington
Conditions
Parenting, Child Behavior, Child Rearing
Interventions
Triple P-Level 2, Play Nicely, Usual care
Other
Lead sponsor
Tulane University
Other
Eligibility
2 Years and older
Enrollment
1,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Not listed Not applicable Interventional Accepts healthy volunteers

Targeting Adolescent Depressive Symptoms Via Brief, Web-Based Interventions

NCT04066985
Conditions
Depression, Depressive Disorder, Behavioral Symptoms, Mood Disorders, Mental Disorders
Interventions
Growth Mindset Online Single-Session Program, Self-Kindness Online Single-Session Program, Supportive Therapy Online Single-Session Program (Control)
Behavioral
Lead sponsor
Child Mind Institute
Other
Eligibility
11 Years to 17 Years
Enrollment
501 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions
SYS6043
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more
Completed No phase listed Observational Accepts healthy volunteers

Diabetic Ketoacidosis: Brain Morphology and Cognition

NCT02443415
Conditions
Diabetic Ketoacidosis
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Completed Phase 2Phase 3 Interventional Results available

Compassionate Use of Omegaven in Children

NCT02370251
Conditions
Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis, Intestinal Atresia, Infant, Premature, Diseases, Cholestasis of Parenteral Nutrition
Interventions
Omegaven
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Obesity, Hyperphagia, Feeding and Eating Disorders
Interventions
Computer Based Response Training Weight Loss Intervention, Generic Response Training Control Intervention
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
18 Years to 38 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Eugene, Oregon
Conditions
Breast Cancer
Interventions
Percutaneous Removal and Margin Ablation
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas